TY - JOUR
T1 - Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas
AU - Cutcutache, Ioana
AU - Suzuki, Yuka
AU - Tan, Iain Beehuat
AU - Ramgopal, Subhashini
AU - Zhang, Shenli
AU - Ramnarayanan, Kalpana
AU - Gan, Anna
AU - Lee, Heng Hong
AU - Tay, Su Ting
AU - Ooi, Aikseng
AU - Ong, Choon Kiat
AU - Bolthouse, Jonathan T.
AU - Lane, Brian R.
AU - Anema, John G.
AU - Kahnoski, Richard J.
AU - Tan, Patrick
AU - Teh, Bin Tean
AU - Rozen, Steven G.
N1 - Funding Information:
Funding/Support and role of the sponsor: This study was supported by the Duke-NUS Signature Research Programs, funded by the Singapore Ministry of Health. The sponsor played no role in the study.
PY - 2015
Y1 - 2015
N2 - Background: Testicular germ cell tumors are the most common cancer diagnosed in young men, and seminomas are the most common type of these cancers. There have been no exome-wide examinations of genes mutated in seminomas or of overall rates of nonsilent somatic mutations in these tumors. Objective: The objective was to analyze somatic mutations in seminomas to determine which genes are affected and to determine rates of nonsilent mutations. Design, setting, and participants: Eight seminomas and matched normal samples were surgically obtained from eight patients. Intervention: DNA was extracted from tissue samples and exome sequenced on massively parallel Illumina DNA sequencers. Single-nucleotide polymorphism chip-based copy number analysis was also performed to assess copy number alterations. Outcome measurements and statistical analysis: The DNA sequencing read data were analyzed to detect somatic mutations including single-nucleotide substitutions and short insertions and deletions. The detected mutations were validated by independent sequencing and further checked for subclonality. Results and limitations: The rate of nonsynonymous somatic mutations averaged 0.31 mutations/Mb. We detected nonsilent somatic mutations in 96 genes that were not previously known to be mutated in seminomas, of which some may be driver mutations. Many of the mutations appear to have been present in subclonal populations. In addition, two genes, KIT and KRAS, were affected in two tumors each with mutations that were previously observed in other cancers and are presumably oncogenic. Conclusions: Our study, the first report on exome sequencing of seminomas, detected somatic mutations in 96 new genes, several of which may be targetable drivers. Furthermore, our results show that seminoma mutation rates are five times higher than previously thought, but are nevertheless low compared to other common cancers. Similar low rates are seen in other cancers that also have excellent rates of remission achieved with chemotherapy. Patient summary: We examined the DNA sequences of seminomas, the most common type of testicular germ cell cancer. Our study identified 96 new genes in which mutations occurred during seminoma development, some of which might contribute to cancer development or progression. The study also showed that the rates of DNA mutations during seminoma development are higher than previously thought, but still lower than for other common solid-organ cancers. Such low rates are also observed among other cancers that, like seminomas, show excellent rates of disease remission after chemotherapy.
AB - Background: Testicular germ cell tumors are the most common cancer diagnosed in young men, and seminomas are the most common type of these cancers. There have been no exome-wide examinations of genes mutated in seminomas or of overall rates of nonsilent somatic mutations in these tumors. Objective: The objective was to analyze somatic mutations in seminomas to determine which genes are affected and to determine rates of nonsilent mutations. Design, setting, and participants: Eight seminomas and matched normal samples were surgically obtained from eight patients. Intervention: DNA was extracted from tissue samples and exome sequenced on massively parallel Illumina DNA sequencers. Single-nucleotide polymorphism chip-based copy number analysis was also performed to assess copy number alterations. Outcome measurements and statistical analysis: The DNA sequencing read data were analyzed to detect somatic mutations including single-nucleotide substitutions and short insertions and deletions. The detected mutations were validated by independent sequencing and further checked for subclonality. Results and limitations: The rate of nonsynonymous somatic mutations averaged 0.31 mutations/Mb. We detected nonsilent somatic mutations in 96 genes that were not previously known to be mutated in seminomas, of which some may be driver mutations. Many of the mutations appear to have been present in subclonal populations. In addition, two genes, KIT and KRAS, were affected in two tumors each with mutations that were previously observed in other cancers and are presumably oncogenic. Conclusions: Our study, the first report on exome sequencing of seminomas, detected somatic mutations in 96 new genes, several of which may be targetable drivers. Furthermore, our results show that seminoma mutation rates are five times higher than previously thought, but are nevertheless low compared to other common cancers. Similar low rates are seen in other cancers that also have excellent rates of remission achieved with chemotherapy. Patient summary: We examined the DNA sequences of seminomas, the most common type of testicular germ cell cancer. Our study identified 96 new genes in which mutations occurred during seminoma development, some of which might contribute to cancer development or progression. The study also showed that the rates of DNA mutations during seminoma development are higher than previously thought, but still lower than for other common solid-organ cancers. Such low rates are also observed among other cancers that, like seminomas, show excellent rates of disease remission after chemotherapy.
KW - Copy number
KW - Exome sequencing
KW - Germ cell tumor
KW - KIT
KW - KRAS
KW - Somatic mutation
KW - Testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=84942983991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942983991&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2014.12.040
DO - 10.1016/j.eururo.2014.12.040
M3 - Article
C2 - 25597018
AN - SCOPUS:84942983991
VL - 68
SP - 77
EP - 83
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 1
ER -